Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebendazole + Lenvatinib in Advanced HCC
NCT04443049Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Lenvatinib + Placebo with Lenvatinib + Mebendazole (2 arms). Primary endpoints: Overall Survival at 15 months, Death at 2 years and 1 more. Status: unknown.
02
Drugs
mebendazole
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04443049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443049.